GB201009108D0 - Compounds for the treatment of clostridium difficile associated disease - Google Patents
Compounds for the treatment of clostridium difficile associated diseaseInfo
- Publication number
- GB201009108D0 GB201009108D0 GBGB1009108.0A GB201009108A GB201009108D0 GB 201009108 D0 GB201009108 D0 GB 201009108D0 GB 201009108 A GB201009108 A GB 201009108A GB 201009108 D0 GB201009108 D0 GB 201009108D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- compounds
- treatment
- associated disease
- clostridium difficile
- difficile associated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000193163 Clostridioides difficile Species 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1009108A GB2480816A (en) | 2010-06-01 | 2010-06-01 | Compounds for the treatment of Clostridium difficile associated diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1009108A GB2480816A (en) | 2010-06-01 | 2010-06-01 | Compounds for the treatment of Clostridium difficile associated diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB201009108D0 true GB201009108D0 (en) | 2010-07-14 |
| GB2480816A GB2480816A (en) | 2011-12-07 |
Family
ID=42371270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB1009108A Withdrawn GB2480816A (en) | 2010-06-01 | 2010-06-01 | Compounds for the treatment of Clostridium difficile associated diseases |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB2480816A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2913330A1 (en) * | 2014-02-27 | 2015-09-02 | Laboratoire Biodim | Condensed derivatives of imidazole useful as pharmaceuticals |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0821913D0 (en) * | 2008-12-02 | 2009-01-07 | Price & Co | Antibacterial compounds |
-
2010
- 2010-06-01 GB GB1009108A patent/GB2480816A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| GB2480816A (en) | 2011-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201403795B (en) | Formulations for the treatment of diabetes | |
| HRP20160397T1 (en) | Compounds for the treatment of clostridium difficile associated disease | |
| GB201021103D0 (en) | New compounds for the treatment of neurodegenerative diseases | |
| SG2014014724A (en) | METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS | |
| EP2544686A4 (en) | Combination methods for treatment of disease | |
| EP2536436A4 (en) | Antimir-451 for the treatment of polycythemias | |
| EP2596007A4 (en) | Process for the preparation of 17-desoxy-corticosteroids | |
| ZA201300546B (en) | Process for the preparation of 3-haloalkylpyrazoles | |
| PT2593423E (en) | Process for the preparation of contrast agents | |
| GB201013060D0 (en) | Compounds for the treatment of clostridium difficile associated disease | |
| IL234796B (en) | Compounds for the treatment of ischemia-reperfusion-related diseases | |
| PT2390246T (en) | Process for the preparation of aminaphtone | |
| GB201013058D0 (en) | Compounds for the treatment of clostridium difficile associated disease | |
| GB201009108D0 (en) | Compounds for the treatment of clostridium difficile associated disease | |
| GB201009085D0 (en) | Compounds for the treatment of clostridium difficile associated disease | |
| GB201009090D0 (en) | Compounds for the treatment of clostridium difficile associated disease | |
| GB201009091D0 (en) | Compounds for the treatment of clostridium difficile-associated disease | |
| GB201009081D0 (en) | Compounds for the treatment of clostridium difficile associated disease | |
| GB201009104D0 (en) | Compounds for the treatment of clostridium difficile associated disease | |
| PT2598504E (en) | Process for the preparation of dimiracetam | |
| GB201106985D0 (en) | Compounds for the treatment of clostridium difficile associated disease | |
| GB201106968D0 (en) | Compounds for the treatment of clostridium difficile associated disease | |
| GB201106970D0 (en) | Compounds for the treatment of clostridium difficile-associated disease | |
| GB201106972D0 (en) | Compounds for the treatment of clostridium difficile-associated disease | |
| GB201009097D0 (en) | Compounds for the treatment of clostridium difficile-associated disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |